Table 4 5-year outcome for patients by TILs in primary cancers & germinal center subgroups. A) All HR-negative cases. B) Triple-negative breast cancers.
Number (%) | 5-Year iDFS (95% CI) | 5-Year dDFS (95% CI) | 5-Year OS (95% CI) | |
|---|---|---|---|---|
(A) All HR-negative cases | ||||
Low sTILs (n = 86) | ||||
≤2 GCs | 31 (36) | 39 (22–55) | 39 (22–55) | 52 (33–68) |
>2 GCs | 55 (64) | 73 (59–83) | 76 (62–85) | 85 (72–92) |
High sTILs (n = 75) | ||||
≤2 GCs | 9 (12) | 100 (−) | 100 (−) | 100 (−) |
>2 GCs | 66 (88) | 89 (79–95) | 89 (79–95) | 94 (84–98) |
(B) Triple-negative breast cancers | ||||
Low sTILs (n = 52) | ||||
≤2 GCs | 16 (31) | 25 (8–47) | 25 (8–47) | 52 (25–74) |
>2 GCs | 36 (69) | 75 (58–86) | 77 (60–88) | 82 (66–92) |
High sTILs (n = 47) | ||||
≤2 GCs | 5 (11) | 100 (−) | 100 (−) | 100 (−) |
>2 GCs | 42 (89) | 90 (76–96) | 90 (76–96) | 95 (82–99) |
